Primaa is a health tech startup developing AI-based software for histological diagnoses, improving a vital step in the detection of cancer.
Primaa's solutions enable them to perform an increasing number of diagnoses while maintaining an unwavering level of reliability.
Primaa was founded in 2018 by Fanny Sockeel, Stéphane Sockeel, & Marie Sockeel. The company is based in Paris, France.
Primaa leverages the latest innovations in AI and deep learning to develop an automated diagnostic software suite for anatomical pathologists.
Primaa's products improve a vital step in the detection of cancer and other pathologies. Primaa fulfills a demand raised by pathology services, where pathologists are faced with a constantly increasing volume of cases.
Primaa is being deployed in several anatomical pathology departments in France, and several million digital images have already been analysed by the startup. The company has built partnerships with several hospitals and laboratories. This field experience represents one of the company’s driving ambitions: to develop the product in close partnership with doctors in order to best fulfill their needs.
Primaa is backed by Fonds Ambition Amorçage Angels or F3A (a fund managed by Bpifrance), Entrepreneurs Investis, 50 Partners, Angels Santé and business angels. The company raised €2M from a Seed Round on Oct 11, 2019.